Abstract 2671
Background
Homeobox (HOX) family consists of 39 genes which act as master regulators in embryonic development. Each of the genes is also known to play key roles in progression of breast cancer, including epithelial to mesenchymal transition, tumor angiogenesis and endocrine therapy resistance. Although there are numerous reports on individual HOX genes and cancer, none of them have comprehensively analyzed the whole gene family. Since HOX genes strongly coordinate within the family during the embryonic period, we considered that the analysis of the whole HOX family is also indispensable in breast cancer.
Methods
We collected 702 breast cancer data from four publicly available array datasets (GSE11121, GSE7390, GSE3494, GSE2990) and performed unsupervised hierarchal clustering into two clusters by the expression of HOX genes. We constructed model formulas for cluster prediction by dividing the samples into learning and validation groups. We used three machine learning methods: support-vector machine (SVM), neural network and Bayes. The model formulas were validated by validation samples. We also used 512 TCGA breast cancer data to calculate covariations of the genes in breast cancer.
Results
By the clustering of four array datasets, the DFS of the two clusters in PAM50-classified luminal B patients were statistically different (p = 0.016), and the gene ontology analysis revealed that the Wnt pathway was activated in the poor prognostic cluster. All cluster prediction models for luminal B sample achieved accuracies of over 90%. From TCGA breast cancer data, we found that HOX genes covariate the most with other HOX genes, especially within the chromosomally proximal groups.
Conclusions
Comprehensive analysis of the whole HOX family lead to the prediction of luminal B breast cancer prognosis. Considering that Wnt signaling controls HOX genes during the embryonic stage, we suppose a Wnt pathway activated, poor prognostic subgroup in luminal B breast cancer which can be identified by the expression of HOX genes. The cluster prediction model by machine learning was acceptable for its future adaptation in clinical settings. We also proved that HOX genes strongly covariate within the gene family in cancer, not only during the embryonic stage.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4868 - Evaluation of markers associated with efficacy of abiraterone acetate plus prednisone (AAP) in patients (pts) with castration-sensitive prostate cancer (mCSPC) from the LATITUDE study
Presenter: Kim Chi
Session: Poster Display session 3
Resources:
Abstract
4837 - LRP2, a potential new biomarker for Chinese younger aged intrahepatic cholangiocarcinoma patients
Presenter: Xiaoliang Shi
Session: Poster Display session 3
Resources:
Abstract
1286 - Reanalysis of the efficacy of molecular targeted agents (MTAs) given in the randomized trial SHIVA01 according to the ESMO ESCAT scale of actionability
Presenter: Aurelie Moreira
Session: Poster Display session 3
Resources:
Abstract
2736 - Comparison of Platforms for Determining Tumor Mutational Burden (TMB) From Blood Samples in Patients With Non-Small Cell Lung Cancer (NSCLC)
Presenter: Jonathan Baden
Session: Poster Display session 3
Resources:
Abstract
5045 - Comprehensive Pan-Cancer analysis of somatic mutations in drug transporters to reveal acquired and intrinsic drug resistance in 3149 metastatic cancer patients
Presenter: Sander Bins
Session: Poster Display session 3
Resources:
Abstract
4577 - Pan-Cancer Genomic Landscape of the Cyclin D1/FGF3,4,19 (11q13) Amplicon Including Associations with HPV Status, and ESR1 and AR Alterations
Presenter: Jennifer Johnson
Session: Poster Display session 3
Resources:
Abstract
5366 - Co-occurrence of NTRK fusions with other genomic biomarkers in cancer patients
Presenter: Xiaolong Jiao
Session: Poster Display session 3
Resources:
Abstract
4084 - Prospective comparative study of next-generation sequencing on fine needle aspirations versus core needle biopsies in cancer patients included in SHIVA02 trial
Presenter: Julien Masliah-Planchon
Session: Poster Display session 3
Resources:
Abstract
6017 - First national External Quality Assessement for the interpretation of somatic variants: assessment of 25 variants in colorectal, lung, ovarian cancers and melanoma in France
Presenter: Etienne Rouleau
Session: Poster Display session 3
Resources:
Abstract
2283 - Prospective testing of circulating tumor DNA in metastatic breast cancer facilitates clinical trial enrollment and precision oncology
Presenter: Andjelija Bujak
Session: Poster Display session 3
Resources:
Abstract